Tipranks Press Release.
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
ResMed is a Hold, valuation offers a low margin of safety despite strong long-term fundamentals and recurring revenue streams. Read more on RMD stock here.
Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
ResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tipranks Press Release.
Find out why Resmed Smart Comfort earned a special mention on TIME's list of 2026's best inventions.
ResMed (NYSE:RMD) reported fourth-quarter financial results on Thursday. The transcript from the company's fourth-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings
ResMed currently trades at $218.94 per share and has shown little upside over the past six months, posting a small loss of 2.7%. The stock also fell short of the S&P 500’s 15.9% gain during that period.
This is the newest page. Registered accounts read further back.